AAVantgarde Bio has received two regulatory milestones for its investigational [...]
AAVantgarde’s AAVB-039 gene therapy, targeting the root cause of Stargardt [...]
AAVantgarde Bio has received two regulatory milestones for its investigational [...]
AAVantgarde’s AAVB-039 gene therapy, targeting the root cause of Stargardt [...]